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Abstract 
Cell labeling with various types of nanomaterial, such as FDA-approved iron oxide 
nanoparticles (IONPs) has become common practice in biomedical research. The low uptake 
of IONPs stimulates the use of transfection agents (TA), but the effect on stability of the 
IONPs and their cellular interactions has received minimal attention. In the present study, we 
evaluated the use of Lipofectamine as a commonly used TA and tested different ratios of TA 
and IONPs. While the TA–IONP complexes are stable in saline, at a high ratio of TA over  
IONP, substantial aggregation occurred in serum-containing media. Even for the highest ratio, 
TA was unable to completely cover the IONPs, resulting in a net negative charge of all 
complexes. At high TA–IONP ratios, more complexes remained surface-associated without 
internalization, resulting in cell death, while at lower TA–IONP ratios, complexes were more 
avidly taken up through fluid-phase pinocytosis and clathrin-mediated endocytosis. At later 
time points, the endocytosed complexes accumulated within the lysosomes and affected the 
appearance of lysosomal structures. The data indicate that TAs should be used with care as, 
depending on the ratio of TA and IONP, the complexes may aggregate, inducing cell death 
and preventing internalization. 
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1. Introduction 
In biomedical research, iron oxide nanoparticles (IONPs) have been widely applied in several 
fields, including targeted drug (1) or gene (2) delivery or magnetic hyperthermia (3), but 
foremost as magnetic resonance imaging (MRI) contrast agents (4). A wide variety of IONPs 
are available, varying in size from a few nanometers to over 1 micrometer and having coating 
materials ranging from synthetic polymers, lipids or dextran to small molecules (5–9). To 
date, dextran-coated iron oxide cores (Endorem in Europe, Feridex in the USA) have been 
most widely applied and have been used extensively in clinical settings for the detection of 
liver pathologies. As one of the sole FDA-approved iron oxide formulations for direct 
intravenous injection, these particles have also been employed more frequently in biomedical 
research as agents for the magnetic labeling of (stem) cells. In 2008, however, Feridex 
production for the US market by AMAG Pharmaceuticals Inc. was stopped, impeding further 
advancements in this field. The particles still remain popular, however, as several clinical 
trials have been set up, all outside of the USA, using Endorem-labeled stem cells to evaluate 
the homing of these cells by serial MR tracking after transplantation (10). Furthermore, owing 
to its long-time use in biomedicine, many data regarding interactions with tissues and cells are 
available, making it an ideal research tool. 
One of the key issues which is still a matter of debate is the possible influence of Endorem 
particles on the cellular wellbeing. Several groups have recently shown that high levels of 
Endorem can affect cell proliferation and cellular morphology (9,11), where intracellular 
degradation may induce reactive oxygen species (ROS) and affect stem cell functionality (12–
16). An in-depth evaluation of the potential (cytotoxic) effects of IONPs on cultured cells is 
therefore of primordial importance in order to stimulate any further progress in this field. 
Furthermore, the efficiency of combining Endorem and transfection agents (TAs) to promote 
cellular uptake is still questionable as several reports hint at an increased uptake (17), whereas 
others describe only surface association and no cellular internalization (18). Such surface-
bound particles have been described to potentially impair cell homeostasis (19) and are also 
more likely to be desorbed from the cells after transplantation in vivo, greatly impeding the 
accuracy of any noninvasive imaging methods. For efficient and accurate MRI cell tracking, it 
is therefore highly beneficial if the IONPs are cell-internalized, where high numbers of cell 
surface-associated IONPs will endanger any further uses of these cells in an in vivo setting. 
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A first step in clarifying the complex interactions between IONPs and cultured cells consists 
of evaluating the uptake mechanism and the intracellular localization of the particles. 
Endorem particles as such are reported to be generally taken up by means of fluid phase 
pinocytosis, reaching quite low intracellular nanoparticles levels (7). To increase cellular 
uptake, it has been suggested to complex Endorem with commercial transfection agents such 
as protamine, poly-L-lysine or Lipofectamine prior to cell labeling(17,20). The effect of the 
transfection agents on the stability of Endorem in physiological buffer and the resulting 
interactions with cultured cells has only rarely been addressed (21). The present work 
therefore aims to investigate the effect of Lipofectamine as one of the most frequently used 
commercial cationic transfection agents. Furthermore, the interactions of these complexes 
with cervical cancer cells (HeLa) has been studied in terms of uptake mechanisms and 
internalization efficiency. The obtained results will allow evaluation og whether complexation 
of Lipofectamine with Endorem affects the stability of the complexes in dispersion and will 
provide insight into the precise intracellular localization and uptake efficiency of the particles. 
This will render it feasible to evaluate whether the addition of Lipofectamine is beneficial or 
detrimental for efficient cell labeling strategies and will help to point out possible 
shortcomings and drawbacks associated with the addition of this transfection agent. 
 
2. Results and discussion. 
2.1. Effect of lipofectamine on size and surface charge of endorem complexes. 
Endorem consists of several 4 nm-diameter iron oxide nanocores that are embedded in a 
neutral dextran matrix, leading to a rather high variation in the number of iron oxide cores per 
particle and in the total size of the particles typically from 60 to 150 nm (5). During 
preparation, small amounts of citric acid are used, which can lead to the presence of several 
carboxyl groups on the dextran shell and induce a slightly negative surface potential (22). 
This negative charge enables efficient complexation with cationic transfection agents, such as 
Lipofectamine. Lipofectamine 2000 as used in the present work is a commercially available 
formulation which consist of the polycationic lipid 2,3-dioleyl-N-
[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoro-acetate and the 
neutral lipid in a 3:1 ratio. This formulation has been described to show lower cytotoxic 
effects compared with previous formulations and has also been found to remain functional in 
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serum-containing media (23). Typically, Endorem and Lipofectamine are mixed in phosphate-
buffered saline (PBS) and allowed to form stable complexes for 1 h prior to further dilution in 
cell media and application to cultured cells (17). Table 1 shows the hydrodynamic diameter as 
measured by dynamic light scattering of pure Endorem or after complexation with 
Lipofectamine at 3 different ratios (100 µg Fe ml
-1
 and 2.5, 5 or 10 µg ml
-1
; these ratios are 
kept constant throughout the work, so that, when lower Endorem quantitities are used later on 
in the work, the amount of Lipofectamine is reduced accordingly) as a function of time and 
the surface potential of the complexes after 30 min. The data show that, in agreement with the 
literature (5), Endorem particles are rather polydisperse in size, but appear to be quite stable in 
PBS. Addition of Lipofectamine moderately increases the size of the complexes, in 
correlation to the amount of Lipofectamine added. Additionally, the complexes appear to be 
formed rapidly as no clear differences in sizes can be seen throughout the entire time-span of 
the experiment. Interestingly, after 30min, the surface charge of the complexes is only slightly 
altered after addition of Lipofectamine as, in all conditions, a net negative surface charge 
ismaintained. This trend was observed in three independent batches of TA–IONP complexes, 
of which the average value is given in Table 1. The relatively low value obtained for free 
Endorem of about -6mV may be explained by the fact that measurements were performed in 
serum-free but Ca
2+
- and Mg
2+
-containing PBS. The latter ions might electrostatically interact 
with the negative surface and hereby result in only a very small negative -potential. The 
standard deviation increases with higher amounts of Lipofectamine, which may indicate an 
increased variability in surface charges between individual complexes. Taken together, these 
data show that the addition of Lipofectamine cannot reverse the overall surface charge of the 
Endorem complexes. We hypothesize that a substantial part of the Endorem surfaces remains 
unbound, while the other part becomes partially or completely coated with Lipofectamine, 
leading to local positive charges, which is beneficial for promoting attachment to the cell 
surface (Scheme 1a, b). 
2.2. Cell association of Endorem–Lipofectamine complexes. 
In order to investigate the interactions of the Endorem–Lipofectamine complexes with 
cultured cells, HeLa cells were exposed to serum-containing cell media containing the 
different complexes at 100 µg Fe ml
-1
 for 8 h and then stained for iron by means of 
diaminobenzidine (DAB)-enhanced Prussian blue staining. The complexes were incubated at 
three different ratios of Endorem and Lipofectamine [100 µg Fe ml
-1
 and 10 (Endo H), 5 
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(Endo M) and 2.5 µl ml
-1
 (Endo L)]. Throughout this work, Lipofectamine concentrations 
were kept at maximally 10 µl ml
-1
 as from earlier studies and our own experience, significant 
cytotoxic effects are induced when using higher Lipofectamine amounts (17). HeLa cells were 
either incubated at 37 °C to allow normal endocytosis to occur or at 4 °C to block all active 
endocytic transport pathways and therefore only allowing cellular attachment of the 
complexes. Incubation also occurred at 37 °C with HeLa cells expressing mutant dynamin, an 
important mediator in several endocytic processes to validate that the TA–IONP complexes 
are internalized by active endocytosis mechanism(s). Figure 1 shows representative images of 
HeLa cells incubated with Endorem–Lipofectamine complexes [100 µg Fe ml-1 and 10, 5 and 
2.5 µl ml
-1
 Lipofectamine (a, b and c)] for cells incubated at 37 °C (first row), cells incubated 
at 4 °C (second row) and mutant dynamin expressing cells (third row). For knockdown of 
dynamin, HeLa dyn K44A cells were used, which express a tetracycline (TET)-inducible 
dominant negative form of dynamin-1, as developed by the S. L. Schmid group (24). The 
images clearly show a great increase in total levels of NP-cell association correlating to higher 
Lipofectamine ratios, which is most pronounced when incubation occurred at 4 °C. Also, for 
the highest amount of Lipofectamine (a), the whole microscopy coverslip was covered with 
aggregates which stained positive for DAB-enhanced Prussian blue, indicating aggregation 
and sedimentation of the complexes in full cell media. These aggregates were only scarcely 
observed for medium or low Lipofectamine ratios (b, c). Scheme 1 presents a schematic 
overview of the stability of dispersed Endorem complexes, for free Endorem in saline (a), 
Lipofectamine-complexed Endorem in saline (b) and Lipofectamine-complexed Endorem in 
serum (c). Note that our data indicate colloidal stability of the complexes in saline (Scheme 
1a, b), whereas aggregates are formed when serum is present (Scheme 1c), which may be 
caused by serum proteins that act as bridges between Lipofectamine covered complexes. 
Incubation of the cells at 4 °C still led to positive DABenhanced Prussian blue stainings in all 
conditions, albeit the total amount of iron detected was clearly lower than those for cells 
incubated at 37 °C. The high level of aggregation and cell surface attachment at high 
Lipofectamine amounts make the difference between 37 °C and 4 °C less obvious, but the 
results for medium and low amounts of Lipofectamine are quite clear. As all active endocytic 
processes are blocked at 4 °C, the positive staining probably indicate cell surface-associated 
complexes (probably aggregates) rather than internalized complexes. This is also suggested 
by the images at lower Lipofectamine concentrations (Fig. 1 b,c), which display positive 
stainings predominantly at the cell periphery. Mutant dynamin expressing cells also clearly 
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display a far lower level of iron than cells incubated at 37 °C, which would indicate that a 
significant portion of the complexes is internalized by means of a dynamin-dependent 
endocytic process. Taken together, these experiments show a clear endocytosis-driven uptake 
mechanism. 
Compared with pure Endorem particles (Fig. 1e), the addition of Lipofectamine clearly 
enhances cellular association of the complexes, for all TA–IONP ratios. Probably, the 
incomplete surface covering of the IONPs by the TA will lead to a high heterogeneity in local 
surface charges, increasing the affinity of charged serum proteins to the complex surface, 
leading to a so-called protein corona (25). Furthermore, it has been found that the thickness of 
the adsorbed protein layer correlates with the size of the NPs (26), hinting at a higher number 
of proteins binding on the complexes with higher Lipofectamine contents. As single charged 
proteins may bind differences complexes, these proteins may act as bridges and thereby 
induce further interaction of the complexes with one another through the bound proteins and 
lead to aggregation (Scheme 1c). The association of serum proteins will also influence the 
way the complexes areinteracting with the cells, as recently shown for silver and gold NPs of 
similar sizes (27) or differences in NP stability and cell–nanoparticle (NP) interactions, 
depending on the type of culture medium used (28). The degree of aggregation clearly 
depends on the ratio of Lipofectamine over Endorem and seemed much less where the 
Lipofectamine amount was kept at 5 ml ml
-1
 or below. These findings (the influence of cell 
media type and Lipofectamine-Endorem ratios) might explain the ambiguity in published data 
where Endorem-transfection agent complexes were described as well internalized (17), led to 
high amounts of cell surface association and internalization (14,22), or solely led to surface 
attachment (18). 
 
2.3. Quantitative uptake and cell-association levels. 
In order to evaluate in more detail the effect of complex composition on the number of 
surface-associated complexes over internalized ones, the amount of cell-associated iron was 
quantified, as shown in Fig. 2. In Fig. 2(a), the total cellular iron content of mutant dynamin 
expressing HeLa cells or HeLa cells incubated for 24 h at 4 or 37 °C with the various 
Endorem–Lipofectamine complexes at 50 µg Fe ml-1 (1.25, 2.5 and 5 µl ml-1 Lipofectamine) 
or in the absence of any complexes (negative controls) is shown. The lower iron content was 
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selected in order to remain within the linear region of the iron determination method and to 
reduce the number of aggregates. The data show that untreated cells contain nearly no iron, as 
expected, but exposure of the cells to the complexes greatly enhances the total cellular iron 
content. The amount of cell-associated complexes increases for higher ratios of Lipofectamine 
over Endorem in all three conditions. The amount of cell-associated iron is minimal at 4 °C in 
every condition, and reflects 40, 49 and 59% of the total cell-associated iron (= the amount of 
iron measured for normal HeLa cells incubated with the complexes at 37 °C under identical 
conditions), for higher Lipofectamine ratios. This suggests that, for higher amounts of 
Lipofectamine, more merely surface-associated iron was found that was not internalized by 
the cells. Data of mutant dynamin-expressing cells show a higher amount of cell-associated 
iron than cells incubated at 4 °C, but significantly less than in cells incubated at 37 °C. This 
indicates that dynamin is only partially involved in the internalization of the complexes and 
that the complexes are probably internalized by different endocytic processes. Based on these 
data, it can be concluded that large amounts of surface-associated iron are intrinsically linked 
to the addition of Lipofectamine. We note that, for an incubation time of 4 h, similar data 
were obtained as for 24 h, with the only difference being that the overall amount of cell-
associated iron was slightly smaller (data not shown). 
Based on these results we decided to use only medium amounts of Lipofectamine for further 
experiments (2.5 µl ml
-1
 and 50 mg Fe ml
-1
 Endorem), since this allows substantial uptake to 
be achieved while avoiding excessive aggregation and sedimentation of large complexes, as 
was observed for the highest TA concentration (cf. Scheme 1a). In order to further elucidate 
the endocytic routes involved, we have applied a number of pharmacological inhibitors (29). 
Incubation of the cells with the complexes and treatment with the carefully selected 
concentrations of inhibitors did not affect cell viability as assessed by lactate dehydrogenase 
and mitochondrial metabolism assays after 4 and 24 h (data not shown). Figure 2(b) shows the  
cellular iron content of control cells or cells treated with pharmacological endocytosis 
inhibitors. From these data, it can be seen that Noco and cytochalasin D (Cyt D), which 
depolymerizes actin microfilaments, both greatly inhibit uptake of the complexes. Maximal 
inhibition (52% reduction) could be noted when cells were exposed to a combination of both 
inhibitors, which is in line with previous reports where Noco + Cyt D have been described to 
completely block all intracellular routing (30). The level of iron found was similar to the 
amount of cell-associated iron obtained when incubation occurred at 4 °C, indicating that this 
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comes from surface-associated complexes. Chlorpromazine (CPM), a cationic amphiphilic 
drug, inhibits the formation of clathrin-coated pits by a reversible translocation of clathrin and 
its adaptor proteins from the plasma membrane to intracellular vesicles (29). Methyl-b-
cyclodextrin (MbCD) depletes the membrane cholesterol content (31), wortmannin (Wort) is 
an inhibitor of phosphatidyl inositol-3-phosphate (PI3K), an enzyme required for the 
completion of macropinocytosis (31,32), and rottlerin (Rott) interacts with protein kinase C 
and inhibits fluidphase endocytosis, which is a mannose receptor-independent and 
unregulated macropinocytotic pathway (33). When the amount of cell-associated iron is 
calculated for every condition and then subtracted by the amount of iron found when cellsare 
treated with Noco and Cyt D (= total block of endocytosis; this value represents the cell 
surface attached particles only), the percentage of complex uptake inhibition can be calculated 
(compared with the level of normal cells incubated with the complexes at 37 °C and also 
subtracted with the value for Noc and Cyt D-treated cells). Please note that, owing to the 
subtractions made, these values are merely indicative and cannot be considered as true 
percentages of uptake and uptake inhibition. Performing these calculations, it was found that 
CPM greatly inhibits cellular internalization of the complexes. Rott leads to a reduction of 
46%, Wort to 31% and MbCD to 29%. These data further support the previous conclusions 
that the complexes appear to be internalized via different endocytic mechanisms, involving 
clathrin-dependent endocytosis, but also partially fluidphase pinocytosis and 
macropinocytosis. A more precise elucidation of the endocytic routes is beyond the scope of 
the current study, but we note that this could be done using cells in which proteins specific for 
endocytic routes are specifically knocked out (29). 
2.4. Effect of Endorem–Lipofectamine complexes on cell viability. 
In order to evaluate the effect of Endorem complexation with Lipofectamine on cell viability, 
HeLa cells were exposed to a wide range of particle concentrations (0, 25, 50, 100 and 200 µg 
Fe ml
-1
) complexed with various ratios of Lipofectamine (2.5, 5 and 10 µl ml
-1
 for 100 µg Fe 
ml
-1
). Figure 3 shows the cell viability data obtained after 24 h incubation measured by an 
lactate dehydrogenase (LDH) assay (Fig. 3a) and an MTT [(3-(4,5- dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay (Fig. 3b). The data show that both assays lead to similar 
results, where any toxic effects are clearer in the MTT assay than in the corresponding LDH 
assay. This may be due to the fact that these assays assess cell viability by measuring different 
parameters, such as mitochondrial functionality and cell membrane permeability for the MTT 
10 
 
and LDH assay, respectively (34,35). The observed differences between these methods may 
therefore signify that the complexes do not appear to perturb cell membrane integrity, but 
rather affect mitochondrial functionality. For cells going into apoptosis, this will result in the 
translocation of cytoplasmic LDH into the extracellular medium. 
The data show that free Lipofectamine at the concentrations used does not induce any 
cytotoxic effects, which is in accordance with the literature, where it has been reported that 
cytotoxic effects only occur when using concentrations above 10 µl ml
-1
 (9,17). When using 
small amounts of Lipofectamine (2.5 µl ml
-1
 for 100 µg Fe ml
-1
), none of the complexes 
appear to have any effect on cell viability up to 200 µg Fe ml
-1
, which is in line with previous 
work (14,15). For medium Lipofectamine concentrations (5 µl ml
-1
 for 100 µg Fe ml
-1
), cell 
viability significantly decreased when incubated at the highest concentration of Endorem (200 
µg Fe ml
-1
). For the highest Lipofectamine concentrations (10 µl ml
-1
 for 100 µg Fe ml
-1
), cell 
viability decreased in an Endorem concentration-dependent manner, significantly decreasing 
cell viability at amounts larger than 100 µg Fe ml
-1
. Regarding the precise mechanism 
involved in the induction of cell death, it is interesting to note that high concentrations of 
Endorem (500 or 1000 µg Fe ml
-1
) with low amounts of Lipofectamine led to much higher 
cellular iron contents than the values obtained here, but did not induce any cytotoxic effects 
(9). As the observed toxicity effects correlate with the occurrence of high amounts of cell-
associated aggregates (Figs 1a and 2a), it can probably be assumed that the substantial 
aggregation and cell surface covering by the complexes impair cell homeostasis, as has also 
been observed for various types of quantum dots (19). 
 
2.5. Confocal analysis of complex internalization. 
To complement the IONP cell adhesion and uptake studies by quantitative iron determination, 
confocal laser scanning microscopy was selected to further evaluate the precise intracellular 
localization of the particles and their uptake routes. To reduce the number of aggregates and 
as high intracellular iron contents might affect fluorescence-based analysis (9), HeLa cells 
were incubated with complexes at 25 µg Fe ml
-1
 (1.25 µl ml
-1
 Lipofectamine) for 4 h. 
Following incubation with the various pharmacological endocytic inhibitors, the presence of 
Endorem was shown by immunostaining for dextran, followed by confocal analysis (Fig. 4). 
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In all conditions, surface-associated complexes can be seen, surrounding the cell cytoplasm. 
In line with the findings described above, treatment of the cells with Noco + Cyt D (Fig. 4e) 
or incubation at 4 °C (Fig. 4c) appeared to block nearly all endocytosis. When cells were 
incubated with Noco alone, some particles were found closer to the cell nucleus, but most 
remained close to the cell periphery (Fig. 4d), which indicates the need of microtubules to 
transport the internalized particles from the cell periphery towards the perinuclear region. This 
is in line with common endocytic transport mechanisms where early endosomes move along 
the microtubules towards the late endosomes, which are located closer to the perinuclear 
region (36,37). In accordance to the data obtained for the cellular iron contents, the images 
show a clear reduction in internalized complexes for cells treated with CPM (Fig. 4i) or Rott 
(Fig. 4f). Wort (Fig. 4g) and MbCD (Fig. 4h) led to only small effects which were hard to 
distinguish from control cells incubated at 37 °C. Interestingly, high levels of complexes were 
found associated with filopodial bridges between HeLa cells (Fig. 4c, bottom right corner), a 
finding which was also made by Ruan et al. (38), who exposed HeLa cells to TAT-peptide 
conjugated quantum dots. These filopodia have also been described to be highly active in  
vesicle shedding and thereby lead to exocytosis of previously internalized particles (38), 
which could also be the case for Endorem–Lipofectamine complexes. 
 
2.6. Colocalization of Endorem complexes with endosomal markers. 
Based on the data obtained earlier, the complexes appear to be internalized through clathrin-
mediated endocytosis, fluid-phase pinocytosis and macropinocytosis. As clathrin-mediated 
endocytosis is arguably the best characterized endocytic mechanism (39) and has been 
described to be involved in the internalization of different types of nanoparticles, including 
IONPs (14,40), this finding correlates well with available literature data. Other, less common, 
endocytosis pathways, such as caveolin- or flotillin mediated endocytosis, may also 
participate in the uptake of the complexes and should therefore be looked into. Caveolae are 
flask-shaped membrane invaginations and are typically associated with cholesterol-rich 
membrane subdomains called lipid rafts; caveolin-mediated endocytosis is one of the main 
endocytic pathways for receptor-independent endocytosis. Flotillin-mediated endocytosis is a 
recently described endocytic uptake mechanism, typical for heparan sulfate proteoglycan 
receptors, and has been described as mediating the uptake of cationic macromolecules such as 
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polyethylenimine (41). The use of pharmacological endocytosis inhibitors, however, can 
sometimes be somewhat misleading as, for some of them, their effect can differ between cell 
types (29). In addition, for several endocytic pathways, such as caveolin- or flotillin-mediated 
endocytosis, no good (noncytotoxic and 100% specific) pharmacological inhibitors are 
commonly available. In order to further unravel the mechanisms involved in the 
internalization of the complexes, the intracellular localization of internalized complexes was 
correlated with those of marker proteins, specific for distinctive endocytic processes (Fig. 5). 
By calculating the number of colocalized pixels for TA–IONP complexes and cellular 
markers, the degree of colocalization can be estimated (percentage of green pixels that 
colocalize with red pixels). Caveolin (9 + 2%)- or flotillin (13 + 3%)-mediated endocytosis do 
not appear to play a significant role (Fig. 5a and b), taking into account the very low levels of 
colocalization. The latter is somewhat surprising as the flotillin-mediated pathway has been 
described as involved in the internalization of cationic macromolecules after electrostatic 
interaction with cell surfacelocated heparan sulfate proteoglycans, which are negatively 
charged (42). One possible explanation could be that the addition of Lipofectamine could not 
overcome the net negative surface potential of the complexes and probably only induces local 
high positive surface charges. The complexes are then probably covered by binding of 
charged serum proteins, leading to the observed aggregation effects and a shielding of the 
positive charges, impeding the electrostatic attraction between the complexes and cellular 
proteoglycans. On the other hand, higher levels of colocalization are found with Lucifer 
yellow (a marker for fluid-phase pinocytosis, 37 + 7%) (43) (Fig. 5c) and transferring (Fig. 
5d, clathrin-specific uptake, 41 + 8%) (39). We note that the reported colocalization 
percentages underestimate the true level of colocalization owing to the presence of cell 
surface-associated complexes that are not internalized. Nevertheless, the relative trends are 
clear and in line with our previous results. 
Based on these data, it appears that a large portion of the particles are internalized through 
fluid-phase pinocytosis, the pathway typically used for noncomplexed Endorem particles. 
Non-complexed Endorem, however, is not attracted to the cell surface and is internalized 
rather inefficiently and with very slow kinetics, making it nearly impossible to include these 
particles in such short exposure conditions as no internalized IONPs can be seen within this 
short time span (7). As a possible explanation of our results we propose the following 
hypothesis, which is summarized schematically in Scheme 2. Based on the net negative 
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surface potential of the complexes, even at the highest Lipofectamine amount, it is quite likely 
that a large portion of Endorem particles remains unbound by Lipofectamine (Scheme 2a). a). 
The Endorem particles that are complexed with high amounts of Lipofectamine probably 
form relatively large aggregates at the cell surface and are probably not endocytosed (Scheme 
2d, see also Fig. 1a). Smaller amounts of Lipofectamine probably lead to smaller complexes 
that may enter the cells through clathrin-mediated endocytosis or macropinocytosis (Scheme 
2b and c). After internalization, the endosomal located complexes travel along the 
microtubules (Scheme 2e), where the complexes will finally enrich in the lysosomal 
compartments of the cell (Fig. 2f). 
 
2.7. Effect of internalized complexes on intracellular endosomes. 
The findings above all point to an active endocytic uptake mechanism, which is in line with 
previous reports in which Endorem complexes have always been found in vesicular structures 
withinthe cell cytoplasm by means of electron microscopy (44), confirmed by the high levels 
of colocalization of the complexes and early endosomal antigen 1 (EEA1)-positive early 
endosomes at early time points (Fig. 6a). 
Interestingly, at early time points the cells show a clear punctuate staining pattern of the 
internalized complexes, indicative of endosomal localization. At later time points, this pattern 
changes dramatically and the complexes are primarily caught in a broad perinuclear ring-like 
structure, which also stains positive for lysosomal associated membrane protein 1 (Lamp-1; 
Fig. 6b). From the transmission image (Fig. 6b4), it can clearly be seen that the complexes 
seem to have concentrated or evenaggregated intracellularly as they can easily be picked up as 
optically dense structures. The Lamp-1 staining pattern, depicting lysosomes, is also 
substantially altered compared with the typical punctuate staining pattern in cells that were 
not exposed to IONPs (Fig. 6b5). The lysosomes appear to have enlarged in size in order to be 
able to contain the large IONP structures. The diffuse staining pattern furthermore hints at the 
possible deformation of the lysosomes. These data are very similar to the findings of Cho et 
al. (45) using CdTe quantum dots, showing significant cell death caused by intracellular 
localization of the quantum dots by mechanisms involving lysosomal enlargement and 
intracellular redistribution at later times. Based on these data, the correct functioning of IONP 
complex-containing lysosomes remains questionable. The increased toxicity of 
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Lipofectamine–Endorem complexes compared with pure Endorem has also been 
demonstrated in several studies, where the addition of the TA resulted in the inhibition of 
stem cell differentiation (46), impeded the functionality of PC12 cells (14) and affected the 
cytoskeleton of primary endothelial cells (9), effects that have not been observed using pure 
Endorem particles. 
The impact of nanoparticles on endocytic transport has already been touched upon by a few 
studies, where peptide-functionalized quantum dots were found not to undergo endocytic 
routing typically associated with the natural ligand the quantum dot was coupled with (47). 
Intra-endosomal aggregation of IONPs has also been described (48) where endocytosed 
complexes have furthermore been found to affect the normal endocytic lifecycle, e.g. delaying 
the maturation of late endosomes into lysosomes (44). Taken together, these data indicate that 
IONP complexes are internalized through typical endocytic pathways, after which they are 
mostly concentrated in the endolysosomes at later time points. Their intra-endosomal 
localization furthermore affects the morphology and the typical appearance of endosomes, 
possibly impeding the normal cellular functionality (45). 
 
3. Conclusion 
The present study shows that the addition of Lipofectamine to Endorem particles leads to the 
rapid formation of complexes that are quite stable in physiological saline, independent of the 
ratio of both components. For every condition, the main part of the surface of the Endorem 
particles remains free of Lipofectamine, resulting in a net negative surface charge in all 
conditions. The presence of serum greatly affects the stability of the complexes, where 
substantial aggregation occurs, the extent of which correlates with the amount of 
Lipofectamine added. When exposed to cultured cells, the free particles are taken up by fluid-
phase pinocytosis whereas complexes formed at low Lipofectamine ratios can be internalized 
by either clathrin-mediated endocytosis or macropinocytosis. The use of larger Lipofectamine 
amounts primarily leads to surface-associated complexes which seem to hinder efficient 
internalization. At later time points, the internalized particles concentrate in a diffuse network 
of lysosomal structures located in the perinuclear region and greatly affect the typical 
structure and distribution of the lysosomal structures. The present work indicates that the use 
of transfection agents such as Lipofectamine does not automatically favor more efficient 
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internalization. The high level of aggregation in the presence of serum, and the inability of 
cultured cells to internalize a large portion of surface-associated aggregates, especially for 
higher amounts of Lipofectamine, hinders their direct use. Differences in cell medium 
composition, the concentration of Endorem or the ratio of transfection agent over Endorem 
will greatly influence the described effects. Considerable attention must be paid to the 
stability of the particles in serum-containing media and on their intracellular behavior and 
possible effects on the endocytic machinery of the cell. 
In light of cytotoxicity of the Endorem–Lipofectamine complexes, the substantial aggregation 
and cell surface covering by nanoparticles can drastically impair cell homeostasis (19), a 
phenomenon that warrants the use of adequate safety precautions when employing 
transfection agents. The size of the aggregates will most likely depend on (a) the 
concentration of IONPs present, (b) the ratio of Lipofectamine over Endorem and (c) the 
presence of additional factors, such as serum proteins. This could be investigated further using 
fluorescence single particle tracking, a microscopy-based technique that was recently reported 
to be able to characterize nanoparticle aggregation in complex fluids (49). Efficient IONP 
internalization, which is of primordial importance to allow for accurate MRI assessment of 
cell migration, can therefore probably be promoted more by reducing the amount of 
Lipofectamine, simply using solely free Endorem at higher concentrations, incubating the 
cells with the complexes in small amounts of serum or using other transfection agents that 
might not induce such heavy aggregation phenomena. 
 
4. Materials and Methods 
4.1. Cell culture. 
HeLa cells were cultured in DMEM/F12 medium (Gibco, Invitrogen, Merelbeke, Belgium) 
supplemented with 10% fetal calf serum, 1% penicillin–streptomycin and 2 mM L-Glutamine 
(Gibco, Invitrogen, Merelbeke, Belgium) in a humidified atmosphere with 5% CO2 at 37 °C. 
HeLa cells expressing a tetracycline-inducible dominant negative form of dynamin (HeLa dyn 
K44A) were maintained in the same medium, further containing 0.2 µg ml
-1
 puromycin, 0.4 
mg ml
-1
 geneticin (Gibco, Invitrogen, Merelbeke, Belgium) and 1 µg ml
-1
 TET (Sigma-
Aldrich, Bornem, Belgium). When HeLa dyn K44A cells were maintained in culture in the 
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presence of TET, only the natural form of dynamin was expressed, leading to fully functional 
cells. In order to induce expression of the mutant dynamin form, HeLa dyn K44A cells were 
given medium without any TET for 24 h prior to exposure of the cells to Endorem. 
4.2. Endorem–Lipofectamine complexation for cell labeling. 
For all magnetic cell labeling experiments, the various TA–IONP complexes were made in 
PBS, at concentrations of 1000 µg Fe ml
-1
 of Endorem and 25, 50 and 100 ml ml
-1
 
Lipofectamine. These complexes were then slightly shaken at ambient temperature to allow 
complex formation, after which part of the stock solution was taken and diluted with complete 
cell medium to reach the required particle concentrations. 
4.3. Dynamic light scattering and surface charge. 
The hydrodynamic diameter and surface charge of the Endorem (Guerbet, Villepinte, 
France)–Lipofectamine (Invitrogen, Merelbeke, Belgium) complexes were measured using a 
Nanosizer instrument (Malvern, Worcestershire, UK). Endorem suspensions in PBS were 
made with an iron content of 25 µg Fe ml
-1
 and measured directly or first combined with 
Lipofectamine at 0.625, 1.25 or 2.5 µl ml
-1
. Hydrodynamic diameters were measured after 5 
min (12 cycles per run) and then repeated every 5 min for up to 25 min. After 30 min, the 
surface charge of the complexes was also measured. Data are expressed as mean + standard 
deviation (n = 3). 
4.4. DAB-enhanced Prussian blue staining of Endorem-treated HeLa cells. 
HeLa cells were seeded in 12 well plates containing glass coverslips at 5*10
4
 cells per well 
and allowed to settle overnight. Then, media were aspirated and fresh medium was given 
containing Endorem–Lipofectamine complexes (100 µg Fe ml-1, 2.5, 5 or 10 µl ml-1 
Lipofectamine) and incubated with the cells for 8 h. Then, media were removed, cells washed 
three times with PBS and fresh medium was given without any particles and cells were 
allowed to further incubate overnight. Next, media were aspirated, cells washed twice with 
PBS and fixed in 2% paraformaldehyde (PFA) for 15 min at ambient temperature. An adapted 
DAB-enhanced Prussian blue staining protocol by Schroeter et al. (50) was used in which the 
cells were incubated with the Prussian blue reagent [6% HCl mixed (1:1) with 2% potassium 
ferrocyanide (II) hydrate; Sigma-Aldrich, Bornem, Belgium] for 45min at 37 °C. Finally, the 
coverslips were mounted on glass microscopy slides and the samples were imaged by optical 
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microscopy (Olympus BX51TF, Olympus, Tokyo, Japan) at a 400x magnification. Images 
were collected using an Infinity 2 camera (BFi Optilas, Alphen aan den Rijn, the 
Netherlands). 
4.5. Cell viability. 
Cell viability was quantitated by means of both an LDH assay (Promega, Madison, WI, USA) 
and an MTT assay. To this end, HeLa cells were seeded at 50 000 cells per well in 96-well 
plates and incubated with Endorem–Lipofectamine complexes at 0, 25, 50, 100 or 200 µg Fe 
ml
-1
 and 2.5, 5 or 10 µl ml
-1
 Lipofectamine per 100 µg Fe ml
-1
. After 2, 4, 8 and 24 h, both an 
LDH-assay and an MTT assay were performed according to the manufacturer’s protocols. 
Untreated cells were assayed as a control reference, and untreated cells exposed to 0.1% 
Triton X-100 for 15 min were used as negative controls. To verify the lack of interference of 
the Endorem–Lipofectamine complexes with the LDH-assay, particle-incubated cells were 
also treated with 0.1% Triton X-100 for 15 min and were found to lead to similar toxicity 
levels as the negative controls. For the MTT assay, background levels generated by 
aggregated Endorem–Lipofectamine complexes were assessed by measuring the absorbance 
of HeLa cells incubated with the various complexes, but not treated with the MTT salt. This 
value was then subtracted from the value obtained for complex-treated cells which were 
incubated with the MTT salt. 
4.6. Quantitative cellular iron determination. 
Quantitative determination of cellular iron contents was carried out by a colorimetric assay 
using the disodium salt of 4,5-hydroxy-1,3-benzenedisulfonic acid (Tiron; Acros Organics, 
Geel, Belgium) as described previously (40). HeLa (or HeLa dyn K44A) cells were seeded in 
96 well plates at 2*10
4
 cells per well and allowed to settle overnight and incubated for another 
24 h to let the cells reach logarithmic growth phase and to induce expression of mutant 
dynamin in HeLa dyn K44A cells. HeLa dyn K44A cells were incubated with medium 
containing Endorem–Lipofectamine complexes (50 µg Fe ml-1; 1.25, 2.5 or 5 ml ml-1 
Lipofectamine) in the presence or absence of TET for 4 or 24 h prior to iron determination. 
HeLa cells were also treated with pharmacological endocytosis inhibitors (see below) or 
incubated at 4 °C. Endorem–Lipofectamine complexes were also incubated in wells 
containing cell culture medium, but without any cells. 
4.7. Pharmacological endocytosis inhibitors. 
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To study the uptake pathway of Endorem–Lipofectamine complexes in more detail, several 
pharmacological inhibitors of endocytosis, i.e. Cyt D, Noco, MbCD, Wort, Rott and CPM 
(Sigma-Aldrich, Bornem, Belgium) were used. The optimal concentration of each type of 
inhibitor or mixture was first evaluated to maximize their efficacy and rule out any toxic side 
effects. The following concentrations were then selected: Cyt D, 25 µg ml
-1
; Noco, 20 µM; 
MbCD, 5mM; Wort, 100 nM; Rott, 2 µM; CPM, 10 µg ml
-1
. Cyt D+ Noco were also used 
together at 25 µg ml
-1
 and 20 µM, respectively. HeLa cells were pretreated with the inhibitors 
for 1 h prior to incubation with Endorem–Lipofectamine complexes (25 µg Fe ml-1; 1.25 µl 
ml
-1
 Lipofectamine), again in the presence of the inhibitors for 4, 8 or 24 h. 
4.8. Confocal analysis of particle uptake. 
HeLa cells were seeded in 12 well plates containing glass coverslips at 5*10
4
 cells per well 
and allowed to settle overnight. After pharmacological endocytosis inhibitor pre-treatment, 
HeLa cells were exposed to Endorem–Lipofectamine complexes (25 µg Fe ml-1; 1.25 µl ml-1 
Lipofectamine) for 4 h, after which the cells were incubated with 5 µg ml
-1
 Cell Mask Orange 
(Molecular Probes, Merelbeke, Belgium) for 5 min at 37 °C, followed by fixation of the cells 
in 2% PFA and permeabilization with 0.1% Triton X-100 for 10 min at ambient temperature. 
After fixation and permeabilization, Cell Mask Orange colors the whole cytoplasm. Cells 
were then blocked in PBS containing 10% goat serum (Invitrogen, Merelbeke, Belgium) and 
2% bovine serum albumin for 1 h at ambient temperature. Next, cells were incubated with 
primary murine antidextran antibody (no. 14533; 1:1000; Stem Cell Technologies, 
Vancouver, Canada) in blocking solution for 2 h at ambient temperature, followed by three 
washing steps with blocking solution and incubation with secondary Alexa Fluor488-
conjugated goat antimouse antibody (1:250; Molecular Probes, Leiden, the Netherlands) for 1 
h at ambient temperature. Subsequently, cells were washed three times with blocking solution 
and mounted using ProLong Gold Antifade Reagent containing DAPI (Molecular Probes, 
Leiden, the Netherlands) for nuclear counterstaining. Samples were imaged with a Nikon C1 
confocal laser scanning microscope (Nikon Belux, Brussels, Belgium) and images processed 
with the Nikon EZ-C1 3.91 imaging software (Nikon Belux, Brussels, Belgium). 
4.9. Confocal analysis of intracellular markers. 
HeLa cells were seeded in 12 well plates containing glass coverslips at 5*10
4
 cells per well 
and allowed to settle overnight. For short term exposure, cells were then incubated with 
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Endorem–Lipofectamine complexes (25 µg Fe ml-1; 1.25 µl ml-1 Lipofectamine) for 1 h at 10 
°C followed by a 15 min chase at 37 °C in fresh medium not containing any complexes. Cells 
were then fixed and permeabilized as described above. Next to Endorem, the following 
markers were also visualized by means of immunocytochemistry: flotillin-1 (polyclonal rabbit 
antiflotillin-1; no. ab41927, 1:200, Abcam, Cambridge, UK), caveolin-1 (polyclonal rabbit 
anticaveolin-1; no. ab2910, 1:500, Abcam, Cambridge, UK) and EEA-1 (polyclonal rabbit 
antiEEA-1; no. ab2900, 1 mgml1, Abcam, Cambridge, UK). They were detected using a 
secondary Rhodamine Red-conjugated goat antirabbit antibody (1:250; Molecular Probes, 
Leiden, the Netherlands). Alternatively, cell media were supplemented with human transferrin 
conjugated with Alexa Fluor 633 (hTF; Molecular Probes, Leiden, the Netherlands) at 15 µg 
ml
-1
 or Lucifer yellow (1 mg ml
-1
) and imaged directly, after immunodetection of Endorem 
and detection of Lucifer yellow (rabbit IgG antilucifer yellow quenching antibody (Molecular 
Probes, Leiden, the Netherlands) and secondary Rhodamine Red-conjugated goat antirabbit 
antibody). For hTF and Lucifer yellow studies, Endorem complexes were incubated together 
with the endocytic probes at 37 °C for 30 min directly. For long-term exposure, HeLa cells 
were incubated with the complexes for 8 h at 37 °C, followed by additional incubation 
overnight in complex-free medium to allow internalization and endocytic routing. After 
fixation and permeabilization, lysosomes were detected by primary polyclonal rabbit 
antilamp-1 antibody (no. ab24170, 1 µg ml
-1
, Abcam, Cambridge, UK) and secondary 
Rhodamine Red-conjugated goat–antirabbit antibody (1:250; Molecular Probes, Leiden, the 
Netherlands). After mounting with ProLong Gold Antifade Reagent containing DAPI, 
samples were imaged with a Nikon C1 confocal laser scanning microscope. Colocalization 
was then analyzed for cell-internalized particles using ImageJ (NIH, USA) and the degree of 
colocalization was calculated using the colocalization analysis plugin, using 25 iterations and 
Fay randomization (MBF collection by Tony Collins). 
4.10. Statistical analysis. 
All data are expressed as mean + standard deviation unless indicated otherwise. To determine 
statistical significance of one group with respect to the control (iron uptake) data were 
analyzed using Student’s t-test. In all cases, the degree of significance is indicated when 
appropriate (*p<0.05; **p<0.01; ***p<0.001). 
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Scheme Legends 
 
Scheme 1. Schematic overview of (a) free Endorem in saline, (b) Endorem complexed with 
Lipofectamine in saline, and (c) Endorem complexed with Lipofectamine in serum-containing 
media. 
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Scheme 2. Schematic overview of the hypothetical model explaining the different interaction 
processes between cells and Endorem complexes. (a) Free Endorem is taken up by fluid-phase 
pinocytosis (7), whereas complexes with low TA/IONP ratios are more probably internalized 
by (b) clathrin-mediated endocytosis or (c) macropinocytosis. The exact internalization 
pathway may depend on the size of the complexes. (d) Complexes with higher TA–IONP 
ratios appear to primarily remain attached to the cell surface. (e) Endocytosed complexes are 
routed along the microtubules towards late endosomes and lysosomes. (f) At later time points, 
fusion of late endosomes and lysosomes probably results in lysosomal expansion and 
deformation of mature lysosomes. 
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Figure Legends. 
 
Figure 1. Cellular internalization of Endorem–Lipofectamine complexes occurs via an 
endocytic process. Representative optical micrographs of DAB-enhanced Prussian blue 
stained HeLa cells, indicating the presence of iron (brown color). HeLa cells were incubated 
with Endorem (100 µg Fe ml
-1
) and Lipofectamine [10 (a), 5 (b) or 2.5 (c) µl ml
-1
] complexes 
for 8 h prior to Prussian blue staining. First row: HeLa cells incubated at 37 °C; second row: 
incubation at 4 °C; and third row: mutant dynamin expressing HeLa dyn K44A cells 
incubated at 37 °C. Micrographs of (d) control HeLa cells and (e) HeLa cells incubated with 
Endorem (100 µg Fe ml
-1
) for 8 h at 37 °C without Lipofectamine. Scale bar: 50 µm. 
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Figure 2. Effects of pharmacological endocytosis inhibitors on Endorem–Lipofectamine 
uptake. (a) Quantitative cell-associated iron levels for HeLa cells incubated under different 
conditions: 1) normal HeLa at 4 °C (dark gray), 2) mutant dynamin HeLa dyn K44A cells at 
37 °C (light gray) or 3) normal HeLa cells at 37 °C (medium gray) for 24 h with the various 
complexes at low, medium and high Lipofectamine ratios. (b) Quantitative cell-associated 
iron levels after 24 h for HeLa cells incubated with Endorem–Lipofectamine complexes at 
medium Lipofectamine contents at 37 °C in the absence of any other additives or in the 
presence of pharmacological endocytosis inhibitors: Noco, 20 µM; Cyt D, 25 µg ml
-1
; Noco + 
Cyt D, 20 µM and 25 µg ml
-1
, respectively; Rott, 2 µM; Wort, 100 nM; MbCD, 5 mM; CPM, 
10 µg ml
-1
. (a, b) Data are presented as means + standard deviation (n = 10). The degree of 
significance for inhibitor-treated cells compared with control cells incubated with the 
complexes at 37 °C is indicated where appropriate (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 3. Effects of complex exposure on cell viability. HeLa cells were incubated at 37 °C 
with various concentrations of Endorem (0, 25, 50, 100 or 200 µg Fe ml
-1
) and Lipofectamine 
[2.5 (Lo; dark gray), 5 (Me; light gray) or 10 µl ml
-1
 (Hi; medium gray) per 100 µg Fe ml
-1
] 
complexes for 24 h after which the cell viability was assessed by means of (a) an LDH and (b) 
an MTT assay. Data are presented as relative values compared with untreated control cells as 
mean + standard deviation (n = 10). The degree of significance in cell viability between 
treated cells and untreated cells is indicated where appropriate (*p<0.05, **p<0.01, 
***p<0.001). 
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Figure 4. Representative confocal images of HeLa cells incubated with Endorem–
Lipofectamine complexes (25 µg Fe ml
-1
; 1.25 ml ml
-1
 Lipofectamine) for 4 h, which were 
then stained for dextran (green) and cell cytoplasm (orange). The following conditions are 
shown: (a) HeLa cells incubated at 37 °C; (b) mutant dynamin-expressing HeLa cells, (c) 
incubated at 4 °C and in the presence of (d) 20 µM Noco, (e) Noco + Cyt D, 20 µM and 25 µg 
ml
-1
, respectively, (f) 2 µM Rott, (g) 100 nM Wort, (h) 5 mM MbCD, or (i) 10 µg ml
-1
 CPM. 
The images shown are merged images of the green and orange channels. In the bottom corner, 
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a magnified image (green channel only) is shown of the area indicated by the white rectangle 
in the main image. Scale bars, 50 µm. 
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Figure 5. Representative confocal images of HeLa cells incubated with Endorem–
Lipofectamine complexes (25 µg Fe ml
-1
; 1.25 µl ml
-1
 Lipofectamine) for (a, b) 15 min or (c, 
d) 30 min, which were then stained for dextran (green, first row), and intracellular markers 
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(red, second row). A merged image of the complexes and the intracellular marker is shown in 
the third row, where colocalized spots appear in yellow. Images are shown for the following 
endocytic markers: (a) caveolin-1, (b) flotillin-1, (c) lucifer yellow and d) transferrin. A high 
magnification image of the area highlighted by a white rectangle in the merged image is 
shown at the bottom of the image. The number in the top-right corner of the merged images 
indicates the percentage of colocalization of Endorem with the respective intracellular marker. 
Scale bars, 50 µm. 
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Figure 6. Representative confocal images of HeLa cells incubated with Endorem–
Lipofectamine complexes (25 µg Fe ml
-1
; 1.25 µl ml
-1
 Lipofectamine) for (a) 15 min or (b) 8 
h followed by overnight post-incubation in particle free-medium, which were then stained for 
dextran (green, first row), and intracellular markers (red, second row). A merged image of the 
complexes and the intracellular marker is shown in the third row, where colocalized spots 
appear in yellow. Images are shown for the following: (a) EEA-1; (b) Lamp-1. A high 
magnification image of the area highlighted by a white rectangle in the merged image is 
shown at the bottom of the image. (b4) The transmission image of the cell shown in (b1–3). 
(b5) A representative confocal image of an untreated HeLa cell stained for Lamp-1. The 
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number in the top-right corner of the merged images indicates the percentage of colocalization 
of Endorem with the respective intracellular marker. Scale bars, 50 µm. 
